Multiple Myeloma News


Here are all the latest news articles written by The Beacon’s staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Oct 26, 2014 8:33 pm | 13 Comments ]
New Criteria For The Diagnosis Of Multiple Myeloma And Related Disorders

The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

The criteria have been published in The Lancet Oncology and are ac­com­panied by recommendations for monitoring and updated criteria for other related plasma cell disorders.

The new diagnostic criteria represent a paradigm shift in the approach to multiple myeloma and will have considerable impact on the management of the disease.

For decades, the diagnosis of multiple myeloma required the presence of “end-organ” damage that could be attributed to the underlying plasma cell disorder. Thus, …

Read the full story »
[ by | Oct 14, 2014 8:59 am | 8 Comments ]
British Researchers Document Potential Solution For Revlimid Gastrointestinal Side Effect

The results of a small British study may lead to fewer myeloma patients suf­fer­ing from diarrhea while taking Revlimid.

In a short article published last week, researchers from the Royal Marsden Hospital in London report that a condition known as “bile acid mal­ab­sorp­tion” appears to be a frequent cause of the diarrhea experi­enced by some patients during treatment with Revlimid (lena­lido­mide).

The researchers also found that the bile acid mal­ab­sorp­tion and re­sult­ing diarrhea in these patients can be addressed in two ways.

For some patients, reducing consumption of …

Read the full story »
[ by | Oct 9, 2014 5:45 pm | One Comment ]
Panobinostat FDA Review On Schedule, Novartis Says

It seems that panobinostat’s review by the U.S. Food and Drug Ad­min­is­tra­tion (FDA) may be on track after all.

A spokeswoman for Novartis (NYSE:NVS), the Swiss pharmaceutical company that is developing panobinostat as a potential new myeloma therapy, has told The Beacon that, contrary to a Beacon report published yesterday, there has not been a delay in the FDA’s review of the drug’s marketing application.

With panobinostat’s review proceeding according to the expected time­table, there need not be concern that the FDA has uncovered un­ex­pected issues with …

Read the full story »
[ by | Updated: Oct 9, 8:00 am | One Comment ]
FDA Delays Decision On Panobinostat New Drug Application

The U.S. Food and Drug Administration (FDA) is giving itself an extra two to three months to decide whether to approve panobinostat as a new treatment for mul­ti­ple myeloma.

The FDA had been expected to reach a decision on the panobinostat new drug application by last Tuesday.  Now, however, a decision is unlikely to occur until the end of November or sometime in December.

The Swiss pharmaceutical company Novartis (NYSE:NVS) filed an ap­pli­ca­tion with the FDA in March to have panobinostat, in combination with Velcade (bortezomib) …

Read the full story »
[ by | Sep 3, 2014 7:39 am | 9 Comments ]
Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade

Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.

Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States.  Sucrets lozenges are marketed by Insight Pharmaceuticals.

The Karmanos researchers conducted laboratory tests of dyclonine’s activity against the so-called “RPMI8226″ line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …

Read the full story »
[ by | Aug 27, 2014 9:52 pm | 6 Comments ]
OncoPep Begins Sponsorship Of The Myeloma Beacon

OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.

OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immuno­therapy is PVX-410, a cancer vac­cine based on re­search in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.

“OncoPep’s decision to support The Myeloma Beacon is yet another ex­ample of a forward-looking organi­za­tion finding itself aligned …

Read the full story »